



CA 72-4⁺ TUMOR MARKER ASSAY FOR THE MEASUREMENT OF TUMOR ASSOCIATED GLYCOPROTEIN TAG-72

The Fujirebio Diagnostics, Inc. (FDI) CA 72-4 Tumor Marker Assay is used for the quantitative measurement of TAG-72 in human serum and plasma. TAG-72 is predominantly expressed in the malignant tumors of the gastrointestinal tract.

■ Antibody/Antigen Components

The CA 72-4 RIA assay from FDI uses 2 monoclonal antibodies: cc49 and B72.3 in a forward sandwich format. These antibodies react with the TAG-72 antigen in serum or plasma.

■ Quality Manufacturing

The CA 72-4 Assay is manufactured in a proven high-quality process that is ISO 9001 certified.

Publications:


1. Spila, Antonella, et al: "Clinical Utility of CA 72-4 Serum Marker in the Staging and Immediate Post Surgical Management of Gastric Cancer Patients," *Anticancer Research*. (1996)

Research in this publication is used to illustrate the benefits of using CA 72-4 in conjunction with CA 19-9 or CEA. The work completed in this study could be useful in the monitoring of gastric cancer.

2. Kodama, Issei, et al: "The Clinical Efficacy of CA 72-4 as a Serum Marker for Gastric Cancer in Comparison with CA 19-9 and CEA." *INT Surgery*. (1995)

This study is used to demonstrate the effectiveness of CA 72-4 in monitoring the levels of TAG-72 in Gastric Cancer in comparison to CA 19-9 and CEA.

*Not for sale in the United States.



FDI: THE TRUSTED NAME IN ONCOLOGY DIAGNOSTICS

In the field of oncology diagnostics, Fujirebio Diagnostics, Inc. (FDI) is the name people trust. Formerly Centocor Diagnostics, we pioneered the development of monoclonal antibody technology. Today, FDI is still the unparalleled leader in tumor marker assays worldwide, with innovative products that are unmatched in quality and dependability. FDI's extensive menu of diagnostic products sets the standard for excellence:

- Supported by thousands of peer-reviewed articles
- Endorsed by prestigious academic institutions and medical centers worldwide
- Proven manufacturing process and ISO 9001 certified quality system
- Distributed worldwide by leading healthcare organizations

FDI's Tumor Marker Assays include:

CA 125II™* (Ovarian Cancer) – Used for the quantitative determination of OC 125-defined antigen in serum of women with primary epithelial invasive ovarian cancer, excluding those with cancer of low malignant potential.

CA 19-9™* (Pancreatic Cancer) – Used for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas.

CA 15-3®* (Breast Cancer) – Used for the quantitative determination of DF3-defined antigen in serum or plasma of patients previously treated for stage II or stage III breast cancer.

CYFRA 21-1™* - FOR RESEARCH USE ONLY - The CYFRA 21-1 assay utilizes two antibodies, KS 19.1 and BM19.21 to measure the elevated levels of cytokeratin 19 fragments in serum.

CA 72-4®+ - FOR RESEARCH USE ONLY - CA 72-4 is an *in vitro* test for research use only that quantitatively measures TAG-72 in blood and serum.

Other Diagnostic Products:

FITC Anti-Rabies Monoclonal Globulin – Used in the direct fluorescent antibody procedure for the *in vitro* detection of rabies in brains and submaxillary glands.

For more information, call +1.610.240.3800 or visit www.fdi.com

* These products are registered in compliance with the European CE mark.

+ Not for distribution in the United States.

Fujirebio Diagnostics
201 Great Valley Parkway
Malvern, PA 19355

610.240.3800
610.240.3825 fax
www.fdi.com

LEADERSHIP DEPENDABILITY INNOVATION